CASE REPORT
Well-known symptoms, new disease – a case of SARS-CoV-2 infection in an eight-year-old boy
1
Department of Paediatrics and Immunology with Nephrology Unit, Polish Mother’s Memorial Hospital Research Institute in Lodz, Poland
Submission date: 2021-11-19
Final revision date: 2022-01-02
Acceptance date: 2022-01-14
Publication date: 2022-03-23
Pediatr Pol 2022;97(1):66-70
KEYWORDS
acetylsalicylic acidintravenous immunoglobulinspaediatric inflammatory multisystem syndrome associated with SARS-CoV-2 infectiondisease associated with SARS-CoV-2 infection
TOPICS
ABSTRACT
Paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 infection (PIMS-TS) is a new disease in children, connected with the COVID-19 pandemic. The main cause of this disease is dysregulation of the immune homeostasis.
We report the first case of PIMS-TS in the Polish Mother’s Memorial Hospital Research Institute in Lodz.
Many non-specific symptoms presented by the patient were the cause of the primary care physician’s therapeutic failure, which resulted in the boy being transferred to the district hospital and then to the institute in Lodz. During the complex diagnostic process anti-SARS-CoV-2 antibodies in the IgM and IgG classes were detected. The initial diagnosis of PIMS-TS was made, and treatment with immunoglobulins and acetylsalicylic acid was initiated. The patient’s condition improved the following day.
The aim of this report is to emphasize that typical symptoms do not always determine known disease entities, and to point out the need to constantly improve one’s knowledge.
We report the first case of PIMS-TS in the Polish Mother’s Memorial Hospital Research Institute in Lodz.
Many non-specific symptoms presented by the patient were the cause of the primary care physician’s therapeutic failure, which resulted in the boy being transferred to the district hospital and then to the institute in Lodz. During the complex diagnostic process anti-SARS-CoV-2 antibodies in the IgM and IgG classes were detected. The initial diagnosis of PIMS-TS was made, and treatment with immunoglobulins and acetylsalicylic acid was initiated. The patient’s condition improved the following day.
The aim of this report is to emphasize that typical symptoms do not always determine known disease entities, and to point out the need to constantly improve one’s knowledge.
REFERENCES (13)
1.
European Centre for Disease Prevention and Control. Paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children – 15 May 2020. ECDC, Stockholm 2020.
2.
Gruber CN, Patel RS, Trachtman R, et al. Mapping systemic inflammation and antibody responses in Multisystem Inflammatory Syndrome in Children (MIS-C). Cell 2020; 183: 982-995.e14.
3.
Jiang L, Tang K, Levin M, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis 2020; 20: e276-e288.
4.
Consiglio CR, Cotugno N, Sardh F, et al. The immunology of multisystem inflammatory syndrome in children with COVID-19. Cell 2020; 183: 968-981.e7.
5.
Lacina L, Brábek J, Fingerhutová S, et al. Pediatric Inflammatory Multisystem Syndrome (PIMS) – potential role for cytokines such is IL-6. Physiol Res 2021; 70: 153-159.
6.
Okarska-Napierała M, Ludwikowska K, Jackowska T, et al. Approach to a child with pediatric inflammatory multisystem syndrome with COVID-19 recommendations by the Polish Pediatric Society Expert Group update February 2021. Przegl Pediatr 2021; 50: 1-11.
7.
Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 2013: 13: 176-189.
8.
Tanner T, Wahezi DM. Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19. Paediatr Respir Rev 2020; 35: 81-87.
9.
Harwood R, Allin B, Jones CE, et al. PIMS-TS National Consensus Management Study Group. A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process. Lancet Child Adolesc Health 2021; 5: 133-141.
10.
Rodriguez-Gonzalez M, Castellano-Martinez A, Cascales-Poyatos HM, et al. Cardiovascular impact of COVID-19 with a focus on children: a systematic review. World J Clin Cases 2020; 8: 5250-5283.
11.
Schvartz A, Belot A, Kone-Paut I. Pediatric inflammatory multisystem syndrome and rheumatic diseases during SARS-CoV-2 pandemic. Front Pediatr 2020; 8: 605807.
12.
Generalić A, Davidović M, Kos I et al. Hematuria as an early sign of multisystem inflammatory syndrome in children: a case report of a boy with multiple comorbidities and review of literature. Front Pediatr 2021; 9: 760070.
13.
Okarska-Napierała M, Zalewska E, Kuchar E. Fever and diarrhea as the only symptoms of multisystem inflammatory syndrome in children. Gastroenterology 2021; 160: 968-969.
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
